INTRODUCTION
Increased amounts of immunoglobulin (Ig)G on or within circulating polymorphonuclear leukocytes (PMN)1 from patients with systemic lupus erythematosus (SLE) have been demonstrated previously using qualitative techniques. Unfractionated leukocytes from SLE patients were shown to possess enhanced levels of IgG using an indirect antiglobulin consumption test (1) . Intracellular inclusions of immunoglobulins were demonstrated in PMN from SLE patients by immunofluorescence techniques (2) . Incubation of SLE sera with normal PMN at 37°C in vitro produced immunoglobulin-containing inclusions within the cells (3) . These results have been interpreted as indicating that soluble immune complexes are adherent to and ingested by circulating PMN in vivo in SLE patients. Also, normal PMN have been used to assay for the presence of soluble immune complexes in various sera (4) . The possible contribution of anti-PMN antibodies, however, to the cell-bound immunoglobulins in SLE and other disorders has not been investigated.
A precise quantification of cell-bound IgG can be obtained using recent adaptations ofthe antiglobulin consumption assay. Cases of Felty's syndrome have been studied using this technique with the demonstration of increased amounts of IgG bound to the patients' own PMN (5) . Elevated serum levels of PMN-binding IgG have been observed in a patient with thyroiditis and neutropenia (6) . These studies did not determine, however, whether the neutrophil-associated IgG or serum IgG-PMN binding activity in the described patients was caused by immune complexes or by antibodies to neutrophils.
We have used an antiglobulin consumption technique to quantify the amounts of IgG adherent to SLE or normal PMN. The IgG-PMN binding activity (IgG-PBA) in serum, or serum fractions, also was determined. The results indicate that PMN from SLE patients possess twice the normal amount of cell-bound IgG. Increased levels of IgG-PBA were detected in SLE sera and in serum fractions containing either immune complexes or monomeric IgG. The levels of IgG-PBA in sera, however, correlated best with those in the IgG fractions. These results indicate that although immune complexes may bind to PMN in vivo in SLE patients, antibodies to PMN may contribute as well to the cell-associated IgG.
METHODS
Blood samples. Nonnal control sera and purified neutrophils were obtained from healthy laboratory workers and hospital staff at the Seattle Veterans Administration Hospital. Blood samples were obtained from patients with SLE who were seen at one of the University of Washington-affiliated hospitals or in the offices of practicing rheumatologists in Seattle. All patients fulfilled the American Rheumatism Association criteria for SLE (7) . Neutrophils were purified from 14 SLE patients, and sera were obtained from 38 patients. Serum samples were also obtained from six patients with IgG myeloma or benign IgG monoclonal gammopathy through the courtesy of Dr. Bruce C. Gilliland (University of Washington School of Medicine, Seattle, Wash.). The subclasses ofthe IgG paraproteins were kindly determined by Dr. John Leddy (University of Rochester School of Medicine, Rochester, N. Y.). All sera were heat-inactivated at 560C for 30 min. The sera were then kept at 4°C for 3 d, centrifuged to remove possible cryoglobulins, and were stored in aliquots at -20°C until assayed. After thawing, each serum sample was centrifuged in a Beckman Model B microfuge (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.) for 3 min at 4°C immediately before incubation with PMN.
Purification of PMN. PMN were obtained from fresh whole blood, anticoagulated with EDTA, by centrifugation on Ficoll-Hypaque (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.) gradients followed by sedimentation of erythrocytes with 3% dextran, molecular weight 500,000 (Sigma Chemical Co., St. Louis, Mo.), as described (8, 9) . Residual erythrocytes were lysed by brief hypotonic shock with 0.2% NaCl. These preparations contained 94-98% granulocytes, which were >95% viable by trypan blue dye exclusion. After two further washings with phosphate-buffered saline (PBS) for a total of six washes, the PMN were suspended in 10 mM 2-deoxyglucose in PBS to inhibit interiorization of membranebound IgG (10) and were counted in a clinical hemacytometer in quadruplicate. No erythrocyte membrane fragments were present in Wright's-stained PMN preparations.
Fab anti-F(ab')2 assay. This assay, described in detail (9, 11) , is a quantitative antiglobulin consumption technique that uses the marked solubility difference in 50% saturated ammonium sulfate (SAS) of unbound human 125I-Fab compared to 125I-Fab bound to rabbit antihuman F(ab')2. Human IgG was purified from commercial Cohn fraction II (Schwartz/ Mann Div., Beckton, Dickinson & Co., Orangeburg, N. Y.) by ion exchange and gel filtration chromatography. The F(ab')2 fragments of IgG were obtained by pepsin digestion followed by gel filtration on Sephadex G-150 (Pharmacia Fine Chemicals) (12) . The Fab fragments of IgG were obtained by papain digestion followed by sequential ion exchange chromatography on CM cellulose and DEAE cellulose (13) . After gel filtration on Sephadex G-100, this preparation contained only Fab fragments as determined by double diffusion studies in agar using antisera specific for human Fab or Fc. Radioiodination of the Fab fragments was performed by the iodine monochloride technique (14) .
Antisera to F(ab')2 were raised in rabbits that were bled after 3 mo of biweekly boosting with F(ab')2 in complete Freund's adjuvant. The titer of anti-F(ab')%, which bound 50% of 20 ng 125I-Fab, was determined by precipitation in 50% SAS as described (11) . 0.5-ml aliquots of serial dilutions of antiserum with PBS containing 1% normal rabbit serum (NRS) were incubated with 20 ng 125I-Fab suspended in 0.5 ml PBS containing 10% NRS for 18 h at 4°C. 1 ml of ice-cold SAS was added with stirring. The mixture was allowed to sit at 4°C for 30 min, then was centrifuged at 2,500 g for 30 min at 4°C. The precipitate was washed twice with 50% SAS and was counted in a well-type gamma counter. The percentage of 125I-Fab precipitated by the rabbit anti-F(ab')2 antibodies (%P) was calculated by the formula: %P = 100 (1-[counts per minute A-counts per minute Bl/[counts per minute A-counts per minute C]), where A = 20 ng 125I-Fab, B = the 125 I-Fab bound to anti-F(ab')2 (i.e., precipitated in 50% SAS), and C = l25I-Fab in PBS with 10% NRS precipitated nonspecifically in 50% SAS.
The dilution of anti-F(ab')2 antiserum that bound 50% of 20 ng 125I-Fab was calculated and aliquots of the dilution were used to obtain a standard inhibition curve with 1.5-100 ng monomeric human IgG as follows. On day 1, the IgG in 0.5 ml of PBS with 1% NRS was incubated with the aliquot of anti-F(ab')2 in 0.5 ml PBS with 1% NRS at 4°C. On day 2, 20 ng 125I-Fab was added as before. On day 3, 1.5 ml of SAS was added, and the amount of l25I-Fab in the precipitate was determined as before. IgG bound to PMN was determined using the Fab anti-F(ab')2 assay as described above.
1 ml of normal or SLE serum samples were also fractionated by linear sucrose density gradient (SDG) ultracentrifugation, as described (9) . The gradients were harvested and five approximately equal pools were made containing material >19S, 19S, 7S-19S, 7S, and <7S in size. After dialysis against PBS, each pool was concentrated to an equal volume so that the IgG in the 7S fraction was the same as the original serum IgG concentration; 100 ,ul of each pool, containing 1.0 ,l of NRS, were incubated with 5 x 106 PMN. After six washes, the PMN-bound IgG was quantitated as before.
Pepsint digestion of normal or SLE IgG. The F(ab')2 fragments of purified IgG from normal or SLE sera were prepared by pepsin digestion (12) . IgG fractions were obtained from serum either by gel filtration on G-200 or by ion exchange chromatography on DEAE cellulose equilibrated with 0.01 M phosphate buffer, pH 7.4. After pepsin digestion of IgG, the F(ab')2 fragments were separated by gel filtration on Sephadex G-150 and co'ncentrated to 8 mg/ml. For some studies, pepsin agglutinators (17) were removed by incubating the F(ab')2 fragments with an equal volume of Sepharose 4B-linked normal human F(ab')2 at room temperature for 2 h. The suspension was then centrifuged and' the supernate containing F(ab')2 was de'canted. The amount of binding of F(ab')2 fragments of IgG from normal or SLE sera to normal PMN was detLrmined as for whole IgG using a standard'curve prepared with normal human F(ab')2 (IgG from Cohn fraction II).
Immnunoadsorption' of rabbit antihuman F(ab')2. For some experiments, the rabbit antihuman F(ab')2 antiserum was made highly specific for the Fd portion of IgG. Purified human monoclonal IgMK, IgAK, and IgAX paraproteins were separately coupled to Sepharose 4B (Pharmacia Fine Chemicals). The gels-were equilibrated with borate buffer and were used as solid-phase immunoadsorbents (18) . After sequentially passing an aliquot of anti-F(ab')2 over each immunoadsorbent column, the effluent was concentrated to the original volume. The titer of adsorbed anti-F(ab')2 that bound 50% of 20 ng 1251-Fab was 1:600, compared to a titer of 1:5,000 for the unadsorbed antiserum. The adsorbed anti-F(ab')2 antiserum gave no lines against purified human IgM and IgA paraproteins, or against purified K-and X-light chains by double diffusion studies in agar. Furthermore, amounts of IgM or IgA over 200-fold greater than that ofIgG were necessary to produce comparable degrees of inhibition of binding of the adsorbed antiserum to 125I-Fab.
Heat aggregation of normal human IgG. Human IgG was purified from commercial Cohn fraction II by ion exchange chromatography on DEAE cellulose. After concentration to 20 mg/ml and dialysis against PBS, the IgG was aggregated by heating at 63°C for 11 min. The size distribution of aggregated IgG in the sample was determined by linear SDG ultracentrifugation. Increasing amounts of aggregated IgG were added to PBS or to aliquots of normal serum, both fresh and heat inactivated at 56°C for 30 min. The levels of IgG-PBA in the samples were then determined as outlined above by incubating the serum or PBS containing aggregates with normal PMN.
Immunofluorescent staining of PMN. Normal PMN were incubated with seven normal or nine SLE sera, or with the G-200 IgG pools from these sera, and then washed six times exactly as described for the indirect assay for IgG-PBA in serum. 1 million IgG-coated PMN were then incubated with 25 ,ul of fluorescein isothiocyanate-labeled F(ab')2 fragments of goat antihuman F(ab')2 (N. L. Cappel Laboratories, Inc., Cochranville, Pa.) for 60 min at 0°C. After three washes with ice-cold PBS, the PMN were examined immediately for immunofluorescence using a Zeiss epi-illuminated fluorescent microscope (Carl Zeiss, Inc., New York). Controls consisted of PMN incubated only with PBS before adding the fluorescent antiserum.
Other methods. Antibodies to nuclear antigens (ANA) were determined in the laboratory of Dr. Bruce Gilliland using described techniques (19) . The Raji cell assay was kindly carried out by Dr. Argyrios Theofilopoulos (Scripps Clinic and Research Foundation, La Jolla, Calif.) (20) . The opsonization assay for anti-PMN antibodies was performed in our laboratory as recently described (9) .
Testing for significant differences between groups was performed using Student's t test. Correlations between paired values were tested for significant differences using standard tables. The results of the ANA titers were tested using Spearman's rank correlation method (21 After heating, the mean IgG-PBA of the SLE sera increased by 36% to 70.0+20.6 ng IgG/106 PMN, whereas the normal sera IgG-PBA increased 57% to 36.5±+2.2 ng IgG/106 PMN. These data indicate that with heating, the IgG-PBA of SLE sera did not increase to a greater degree than did that of normal sera.
In addition, the effect on serum IgG-PBA of adding increasing amounts of heat-aggregated normal human IgG to the unheated or heated normal serum samples was determined. The aggregates were equally divided between small (19S or less) and large (>19S) sizes.
The addition of m25 ,ug heat-aggregated IgG/ml offresh normal serum increased the value of IgG-PBA to that of heated serum (Fig. 2) . Adding 25 to 500 ,ug/ml of aggregated IgG to normal heated serum yielded levels of IgG-PBA equivalent to those seen in SLE sera (see below).
IgG-PBA of serum. The amount of IgG that bound to normal PMN after in vitro incubation with heat-inactivated sera from 36 normal individuals, 6 patients with IgG monoclonal paraproteins, and 38 SLE patients was determined. The IgG-PBA (mean±1 SD) of the normal serum samples was 29.2±8.3 ng IgG/ 106 PMN, as recently published (9) . The mean value for the 6 monoclonal IgG sera, whose IgG concentrations varied from 1.4 to 5.8 gm/100 ml, was 30.7±8.5 ng IgG/106 PMN, not significantly increased above normal serum IgG-PBA. (Five of the monoclonal IgG paraproteins wiere of subclass 1 or 3). On the other hand, the mean IgG-PBA for the SLE sera, 53.6±21.3 ng IgG/106 PMN, was significantly greater than the mean values seen with sera from normals or patients with comparably elevated IgG levels (P < 0.001, Student's t test) (Fig. 3) . Furthermore, 22 IgG sera sera FIGURE 3 IgG-PBA in serum samples from 36 normal controls, 6 patients with monoclonal IgG paraproteins, and 38 patients with SLE. The mean value for the SLE sera was significantly increased over the mean observed with the normal or paraprotein-containing sera (P < 0.001, Student's t test). more than 2 SD above normal were found in 11 G-200 excluded pools and in 13 of the 18 IgG pools; 9 sera contained elevated values in both pools (Table I) .
No correlation was observed between the values for IgG-PBA and the IgG concentrations of the SLE G-200 IgG pools, which were between 250 and 1,000 mg/100 ml with a mean of 400 mg/100 ml. . ; o e  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . t . . , . . . . . . . . . . . . . . . Immunoadsorption of anti-F(ab')2. To exclude the possibility that the elevated levels ofIgG-PBA detected in the G-200 excluded pools of the SLE sera were caused by IgM antineutrophil antibodies, the rabbit antihuman F(ab')2 antiserum was rendered specific for the Fd portion of human IgG as outlined in Methods. Compared to the unadsorbed antiserum, however, 30% more normal human IgG was required to produce equal inhibition of binding of the '25I-Fab by the adsorbed anti-F(ab')2 antiserum. Thus, the absolute values of IgG-PBA detected with the adsorbed antiserum were 30% less than those detected with the unadsorbed antiserum. The IgG-PBA of 17 results were observed with normal and SLE F(ab')2 obtained from DEAE-purified IgG after removal ofpepsin agglutinators. These data indicated that IgG antibodies to neutrophils contributed to the elevated IgG-PBA seen with some SLE sera. Immunofluorescence of PMN-bound IgG. These studies were performed to determine whether the elevated IgG-PBA seen with SLE sera could be a result of ANA binding to nuclei of PMN damaged during purification. Seven normal and nine SLE sera with elevated Other studies on SLE sera. 22 SLE sera were examined for the presence of immune complexes using the Raji assay. 15 of these sera were positive, exhibiting >12 ,ug aggregated human IgG equivalents/ml serum. The IgG-PBA was elevated in 16 out of these 22 SLE sera. The absolute levels of serum IgG-PBA were strongly correlated with the results obtained with the Raji assay (r = 0.74, P < 0.001).
The ANA was positive in 21 of these 22 SLE sera. A significant correlation was seen between the ANA titers and the levels of IgG-PBA (r = 0.68, P < 0.002, Spearman's rank correlation method) as well as with the results obtained with the Raji assay (r = 0.61, P < 0.005, Spearman's rank correlation method).
Elevated levels of serum PMN-opsonizing ability were seen in only 3 ofthese 22 SLE sera. Each of these three sera had very high levels of IgG-PBA in whole serum, as well as in both G-200 excluded and IgG pools. These three sera also exhibited the highest ANA titers and the most abnormal values in the Raji assay. Two of these three patients had elevated levels of IgG bound to their own PMN. The absolute PMN count, however, was normal in these three SLE patients with elevated levels of serum PMN-opsonizing ability.
DISCUSSION
Increased amounts of IgG on or in PMN from most SLE patients have been found by other investigators using qualitative or semiquantitative techniques (1, 2) . The objectives of the present experiments were to quantify this PMN-bound IgG and to determine the contributions of soluble immune complexes and anti-PMN antibodies in SLE sera to the levels of IgG-PBA. Since (23, 24) . In addition, IgG anti-PMN antibodies, or other unidentified materials, may have specifically blocked the Fc receptors on the cells. Assays performed with an Fdy-specific antiserum confirmed that the cell-binding activity in the high molecular weight pools was caused by IgG-containing complexes and not by IgM anticell antibodies. Additional evidence for binding of immune complexes in these SLE sera to PMN was the high degree of correlation noted between the values of IgG-PBA and the results of the Raji assay for immune complexes.
The levels of IgG-PBA observed with G-200 IgG pools from normal sera may represent nonspecific adherence or the presence of low levels of anti-PMN antibodies; leukocyte-reactive antibodies have been detected in low titers in normal sera using cytotoxicity assays (25, 26) . The elevated levels of IgG-PBA found in the G-200 IgG pools of SLE sera were concluded to be caused by the presence of IgG antibodies reactive with neutrophils. The finding of greater PMN- binding by F(ab')2 from SLE sera than F(ab')2 from normal sera offers further support for this conclusion. The high degree of correlation between the values of IgG-PBA in the SLE sera and those in the monomeric IgG serum fractions suggests that antineutrophil antibodies may contribute significantly to the elevated levels of IgG-PBA in sera, and possibly to the increased amounts of IgG found on SLE PMN in vivo. Other investigators have described increased levels of coldreactive granulocytotoxic antibodies of undetermined immunoglobulin class in over 50% of 57 SLE sera (26) .
The nature of the stimulus for producing antibodies that bind to neutrophils in SLE is unknown. Their ubiquity suggests that they may result from nonspecific B-cell hyperreactivity (27, 28 (32) . Only one of the five sera was from an SLE patient. Significant correlations were observed in our studies between the levels of serum IgG-PBA and the ANA titers; however, we did not examine for any possible cross-reactivity. Thus, to determine whether these antibodies recognize antigens specific to neutrophils or antigens associated with neutrophils, as well as other cells, will require further studies.
Soluble immune complexes or anticell antibodies could influence PMN function or kinetics in SLE patients. We have previously reported extensive studies on an SLE patient with severe granulocytopenia, offering evidence that IgG antibodies to neutrophils mediated destruction of his cells through an autoimmune mechanism (9) . In other studies, anti-PMN antibodies injected into rabbits resulted in rapid cell depletion by opsonizing neutrophils for ingestion by fixed tissue macrophages in the liver and spleen (33) .
Homologous anti-PMN antibodies studied in vitro inhibited the ingestion of opsonized particles and coated the neutrophils for ingestion by other phagocytic cells (34) . The infrequent detection ofPMN-opsonizing antibodies in our SLE sera may reflect a lower sensitivity of this assay or a failure of the SLE antibodies to opsonize because of a sparse distribution of antigens on the cell surface.
It should be emphasized that the majority of SLE patients (35) , including ours, are not neutropenic. The lack of correlation between the levels of neutrophilbound IgG or serum IgG-PBA and the PMN counts in our patients appears paradoxical. These observations suggest the possible role of other factors, such as antibody-binding characteristics, antigen site density, or phagocytic cell function. Also, neutrophil kinetic studies were not performed on any of these SLE patients. Antibodies or immune complexes that bind to platelets and decreased platelet survival or increased blood megathrombocytes were detected in 75% of SLE patients (36) . The finding of thrombocytopenia in only 14% of SLE patients, however, suggested that a compensated thrombocytolytic state was common in SLE (36) . Further neutrophil kinetic studies in SLE patients will be necessary to establish whether a simmilar situation of increased peripheral destruction and compensated bone marrow production exists for this cell as well.
The interaction of complement with neutrophils also may affect their function or kinetics (37, 38) . Activated complement components have recently been described on circulating PMN from SLE patients (39) . The results of our studies suggest that complement could be activated on the neutrophil surface in SLE patients either through adherent immune complexes or by anti-PMN antibodies.
